BioAxone BioSciences

BioAxone BioSciences is a Boston-based biotechnology company dedicated to transforming the lives of patients with neurotrauma or neurovascular diseases by leveraging its deep understanding of axonal regeneration and neuronal signaling pathways. Building on 20 years of groundbreaking research in axonal regeneration and diseases involving Rho/ROCK signaling, BioAxone’s lead candidate is an orally available ROCK2 inhibitor that restores endothelial cell barriers in cerebral cavernous malformations (CA) and stroke. The company’s pipeline also includes programs developing candidates for the treatment of spinal cord injury.